ClinicalTrials.gg
Enrolling by invitationNCT06828549MOSAICUpdated Mar 5, 2026

MObile Support Adapted to Individual Contexts

An interventional study of MOSAIC and Print Materials in Type 2 Diabetes, sponsored by Vanderbilt University Medical Center. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Vanderbilt University Medical Center.

Planned enrollment
3rd of 18
547 · median 135
Started
2025
with 3 others
No phase
13 of 21
2 open now
Registered
17th of 21
by date

Among the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, and was the 17th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

This behavioral clinical trial evaluates an adaptively tailored, mobile phone-delivered intervention (MOSAIC) designed to support adults managing their type 2 diabetes. Adaptive means the intervention can change over time. Tailored means the intervention may be different for different participants. The main questions the study will aim to answer are:

  1. Does the diabetes education and support delivered via the MOSAIC adaptive mobile phone-delivered intervention improve outcomes more than diabetes education and support delivered via print materials alone? This aim compares the study arms on outcomes such as glycemic management (hemoglobin A1c), diabetes distress, and psychosocial well-being. This aim also compares the study arms on intervention targets (mediators) including diabetes self-efficacy and self-care behaviors.
  2. For whom does the MOSAIC adaptive tailoring approach improve outcomes more than the print materials alone? This aim examines how well the tailoring rules used for the MOSAIC intervention worked for different participants on the outcomes examined in the first aim.

Participants will enroll in a 16-month study with assessments every 4 months. Assessments include completion of an A1c test and a survey. For those assigned to MOSAIC, they will experience 12-months of mobile phone-delivered support with 3 opportunities for intervention tailoring.

Read the detailed description

MOSAIC intervention components include:

  • Monthly coaching sessions (\~30 minutes each) - Persons with diabetes (PWD) will engage in goal setting and skill building relevant to their self-identified diet, exercise, and/or stress management goal
  • Daily one-way and interactive text messages to support the PWD in meeting their goal and supporting medication adherence
  • Weekly interactive text messages asking the PWD to reflect on goal progress followed by personalized feedback from their coach
  • The option to invite an adult support person (SP). SPs may be invited to participate in monthly phone coaching and/or receive text messages (3 one-way texts per week and one interactive text per week) pertaining to supporting the PWD, per the MOSAIC intervention adaptive tailoring rules

PWD participants will be randomized in a parallel design to the MOSAIC adaptive mobile phone-delivered intervention or to print materials alone. The study is powered to detect a 0.5% reduction in hemoglobin A1c. Analyses will examine effects during the intervention (4 and 8 months) and post-intervention (12 months) and sustained effects (16 months). Participants will be analyzed as randomized regardless of withdrawal from the intervention (i.e., intention-to-treat principals) and missing data will be imputed.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • family support
  • social support
  • text message
  • mobile health
  • hemoglobin A1c
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PERSONS WITH DIABETES:

  • Speaks and reads in English
  • 18-75 years old
  • Diagnosed with type 2 diabetes
  • Receiving outpatient care from a partnering clinic
  • Community-dwelling (e.g., not in a nursing facility)
  • Prescribed at least one diabetes medication
  • Owns a mobile phone

SUPPORT PERSONS:

  • Speaks and reads in English
  • 18 years or older
  • Owns a mobile phone

Exclusion criteria

Exclusion Criteria:

PERSONS WITH DIABETES:

  • Unable to communicate by phone
  • Currently pregnant
  • Currently undergoing treatment for cancer (e.g., radiation, chemotherapy)
  • Diagnosed with end-stage renal disease
  • Receiving hospice services*
  • Diagnosed with congestive heart failure
  • Diagnosed with dementia
  • Diagnosed with schizophrenia
  • Demonstrated an inability to receive and respond to a text
  • Does not take medication on his/her own/medication administered by someone else

SUPPORT PERSONS:

  • Demonstrated inability to receive \& respond to a text
  • Unable to communicate by phone
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
547 participants (estimated)

Study arms

  • Experimental
    MOSAIC

    PWD participants will receive MOSAIC components (monthly phone coaching and text message support for goals and medication adherence) for 12 months. PWD participants will receive high-quality print materials upon enrollment and quarterly newsletters on healthy living with diabetes. All SP participants invited by PWD participants assigned to MOSAIC will receive high-quality print materials upon enrollment and quarterly newsletters on healthy living with diabetes. SPs may participate in monthly phone coaching and/or receive text message support tailored to the goal set by the linked PWD.

    Behavioral: MOSAIC · Behavioral: Print Materials

  • Placebo comparator
    Print Materials

    PWD participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on health living with diabetes.

    Behavioral: Print Materials

Interventions

  • BehavioralMOSAIC

    All MOSAIC PWD participants receive monthly phone coaching following a semi-structured protocol plus daily automated text message support. MOSAIC uses the mobile phone-delivered structure and functionality developed for FAMS (NCT04347291). Tailoring rules novel to MOSAIC determine phone coaching protocol content, text message content, and the involvement of a SP. Semi-structured protocols used in prior studies (and in the case of NCT04334109 adapted for mobile phone-delivery) are employed. Per tailoring rules, enrolled SPs may be invited to participate in monthly coaching calls with the PWD and/or receive text messages about supporting the PWD. The study will not assess outcomes or effects among SPs.

    Also known as: Family/friend Activation to Motivate Self-Care (FAMS; NCT04347291), Family Diabetes Self-Management Education and Support (NCT04334109), Standard Diabetes Self-Management Education and Support (NCT04334109), Diabetes Distress Reduction

  • BehavioralPrint Materials

    Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c During Intervention Period

    Hemoglobin A1c assessed by mail-in A1c kits and/or taken from electronic health record (venipuncture or point-of-care) where higher values indicate worse glycemic management

    Time frame: Baseline and 4, 8, and 12 months post-baseline

  2. Change in Hemoglobin A1c Sustained Post-intervention Effects

    Hemoglobin A1c assessed by mail-in A1c kits and/or taken from electronic health record (venipuncture or point-of-care) where higher values indicate worse glycemic management

    Time frame: Baseline and 16 months post-baseline

Secondary outcomes

  1. Change in Diabetes Distress During Intervention Period

    Assessed by the Problem Areas in Diabetes (PAID-5) with scores ranging 0-100 where higher scores indicate more emotional, psychological and social distress related to diabetes management (worse)

    Time frame: Baseline and 4, 8, and 12 months post-baseline

  2. Change in Diabetes Distress Sustained Post-intervention Effect

    Assessed by the Problem Areas in Diabetes (PAID-5) with scores ranging 0-100 where higher scores indicate more emotional, psychological and social distress related to diabetes management (worse)

    Time frame: Baseline and 16 months post-baseline

  3. Change in Psychosocial Well-being During Intervention Period

    Assessed by the World Health Organization - Five Well-Being Index (WHO-5) with scores ranging 0 to 100 where higher scores indicate more well-being (better)

    Time frame: Baseline and 4, 8, and 12 months post-baseline

  4. Change in Psychosocial Well-being Sustained Post-intervention Effect

    Assessed by the World Health Organization - Five Well-Being Index (WHO-5) with scores ranging 0 to 100 where higher scores indicate more well-being (better)

    Time frame: Baseline 16 months post-baseline

Other outcomes

  1. Change in Diabetes Self-efficacy (Outcome & Mediator)

    as assessed by the Perceived Diabetes Self-Management Scale with scores ranging 8 to 40 with higher scores indicating more self-efficacy (better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  2. Change in Diabetes Self-care Quality (Outcome & Mediator)

    Diabetes Self-Management Questionnaire - Revised (DSMQ-R) with scores ranging 0-10 with higher scores indicating more effective self-care behaviors (better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  3. Change in Dietary Behavior (Outcome & Mediator)

    as assessed by Personal Diabetes Questionnaire, Use of Information for Decision Making Scale with scores ranging 1-6 where higher scores indicate more use of dietary information for decision making (better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  4. Change in Dietary Behavior (Outcome & Mediator)

    as assessed by Personal Diabetes Questionnaire, Problem Eating Behavior scale with scores ranging 1-6 where higher scores indicate more problem eating behaviors (worse)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  5. Change in Physical Activity (Outcome & Mediator)

    As assessed by the Physical Activity Scale for the Elderly (PASE) with scores ranging 0-400 where higher scores reflect greater levels of physical activity (better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  6. Change in Physical Activity (Outcome & Mediator)

    As assessed by the Exercise Vital Sign (EVS) with scores ranging 0-1,050 minutes per week of moderate to strenuous physical activity where higher scores indicate more physical activity (better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  7. Change in Diabetes Medication Adherence (Outcome & Mediator)

    as assessed by the Summary of Diabetes Self-Care Activities medications subscale with scores ranging 0 to 7 representing days in the prior week with perfect adherence (higher is better)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

  8. Change in Diabetes Medication Adherence (Outcome & Mediator)

    as assessed by the Adherence to Refills and Medications in Diabetes scale, with scores ranging 11-44 with higher scores indicating more problems with adherence (worse)

    Time frame: Baseline and 4, 8, 12, and 16 months post-baseline

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — After study results are posted on clinical trials, de-identified individual and aggregate survey, clinical, and laboratory data (including raw and recoded data) and associated study documentation (survey codebook; analytic code used in survey and clinical data analyses; standard citation and unique identifier to facilitate attribution of data use) will be made publicly available through the Open Science Framework (OSF).

Supporting information: Statistical analysis plan, Analytic code

Time frame: After study results are posted on clinical trials (required to occur within 1 year of final data collection), scientific data will be submitted to the Open Science Framework (OSF). Under the current repository policies, data will be preserved and available for the wider research community in perpetuity.

Access criteria: Survey, clinical, and laboratory data and associated study documentation (survey codebook; analytic code used in survey and clinical data analyses; standard citation and unique identifier to facilitate attribution of data use) will be shared and made publicly available through OSF as open access. Survey, clinical, and laboratory data will be made available in csv and text format and will not require the use of specialized tools to be accessed or manipulated. All shared data and documentation will be findable and identifiable using the standard data indexing tools in Open Science Framework.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2028, 44 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 44 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828549
Responsible party
Lindsay Mayberry (Principal Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
Feb 14, 2025
Start date
Mar 21, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Mar 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion